• Explore /
  • Poster
  • / Phase 2 study (AARDVARC) of AZD4635 in combination with durvalumab and cabazitaxel in patients (pts) with progressive metastatic castrate-resistant prostate cancer (mCRPC).

Phase 2 study (AARDVARC) of AZD4635 in combination with durvalumab and cabazitaxel in patients (pts) with progressive metastatic castrate-resistant prostate cancer (mCRPC).

Abstract Poster

Authors

null

Teresa Alonso Gordoa

Hospital Universitario de Ramon y Cajal, Madrid, Spain

Teresa Alonso Gordoa , Michael Moses Goodman , Christof Vulsteke , Guilhem Roubaud , Jingsong Zhang , Mamta Parikh , Josep M. Piulats , Analía Azaro , Gareth D James , Riccardo Cavazzina , Eric Gangl , Jeff Thompson , Gayle Pageau Pouliot , Rakesh Kumar , Christopher Sweeney

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04089553

Citation

J Clin Oncol 41, 2023 (suppl 6; abstr 173)

DOI

10.1200/JCO.2023.41.6_suppl.173

Abstract #

173

Poster Bd #

F10

Abstract Disclosures

Similar Posters

First Author: Sumit Kumar Subudhi

First Author: Adam Kessel

First Author: Shahneen Kaur Sandhu

First Author: Carlo Buonerba